The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Anaphylaxis-Anaphylactoid reaction (can be fatal)
Anaphylaxis, when it occurs, develops during the first administration of the drug. Caution and preparedness are vital
Publications
Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2017 Jul;274;2883-2889 — 2017 Jul — 2883-2889
Drug allergens and food--the cetuximab and galactose-?-1,3-galactose story.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2014 Feb;112;97-101 — 2014 Feb — 97-101
Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
The New England journal of medicine 2008 Mar 13;358;1109-17 — 2008 Mar 13 — 1109-17
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
The New England journal of medicine 2004 Jul 22;351;337-45 — 2004 Jul 22 — 337-45